Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 9:11:8277-8284.
doi: 10.2147/CMAR.S215585. eCollection 2019.

Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China

Xiangli Liu  1 , YuFeng Shang  1 , Ling Li  1 , Xudong Zhang  1 , Zhaoming Li  1 , Mingzhi Zhang  1
Affiliations

Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China

Xiangli Liu et al. Cancer Manag Res. .

Abstract

Background: Peripheral T-cell lymphoma (PTCL) is often prone to relapse and progression even after formal first-line treatment, and there is no standard regimen for second-line treatment. What is more, the activity of thalidomide against this type of lymphoma is unknown.

Purpose: The objective of this study was to evaluate the efficacy and safety of GDPT regimen in the treatment of relapsed/refractory peripheral T-cell lymphoma.

Patients and methods: In this retrospective study, gemcitabine, cisplatin, prednisone, and thalidomide (GDPT) combination regimen was used as salvage protocol for PTCL that failed in first-line treatment for 29 patients and it was scheduled to give 6 cycles of GDPT therapy in order to better evaluate the efficacy unless there was evidence of disease progression, unacceptable toxicities, or refusal by the patient.

Results: After a total of 106 cycles of GDPT regimen were administered, the result showed that the disease control rate (DCR) achieved 82.8% and overall response rate (ORR) reached 69.0% with 34.5% complete remission (CR) and 34.5% partial remission (PR). The median progression-free survival (PFS) was 10.0 months (95% CI 6.6-13.4) and median OS was 28.0 months (95% CI 19.2-36.8). And the 1-year PFS rate and 1-year OS rate were 43.6% and 64.6%, respectively. Both hematologic and non-hematologic toxicities were moderate and well tolerated. There was no treatment-related death.

Conclusion: Thalidomide in combination with gemcitabine, cisplatin, prednisone regimen is a new promising approach to treating patients with relapse and refractory PTCL.

Keywords: gemcitabine; peripheral T-cell lymphoma; salvage chemotherapy; thalidomide.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Response rates of GDPT chemotherapy. Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; GDPT, gemcitabine, cisplatin, prednisone, and thalidomide.
Figure 2
Figure 2
Progression-free survival of GDPT with relapsed/refractory PLCL.Abbreviation: GDPT, gemcitabine, cisplatin, prednisone, and thalidomide.
Figure 3
Figure 3
Overall survival of GDPT with relapsed/refractory PLCL. Abbreviation: GDPT, gemcitabine, cisplatin, prednisone, and thalidomide.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130. doi:10.1200/JCO.2008.16.4558 - DOI - PubMed
    1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569 - DOI - PMC - PubMed
    1. Sun J, Yang Q, Lu Z, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138(3):429–434. doi:10.1309/AJCP7YLTQPUSDQ5C - DOI - PubMed
    1. Briski R, Feldman AL, Bailey NG, et al. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood Cancer J. 2014;4:e214. doi:10.1038/bcj.2014.34 - DOI - PMC - PubMed
    1. Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011;2011:623924. doi:10.5402/2011/623924 - DOI - PMC - PubMed